Details for Patent: 9,089,567

Title:	Method of treating cognitive impairments and schizophrenias
Abstract:	The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
Inventor(s):	Jordan; Shaun (Germantown, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita-cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP)
Assignee:	Otsuka Pharmaceutical Co., LTD. (Tokyo, JP)
Filing Date:	Nov 23, 2011
Application Number:	13/303,265
Claims:	1. A method of treating a patient suffering from treatment-resistant schizophrenia, comprising administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof: ##STR00003## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond, wherein the patient is a mammal and the patient fails to respond adequately to antipsychotic drugs which are at least one typical antipsychotic drug and at least one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 2. The method of claim 1, wherein the at least one typical antipsychotic drug comprises two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine. 3. The method of claim 1, wherein the at least one typical antipsychotic drug comprises one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol. 4. The method of claim 1, wherein the at least one typical antipsychotic drug comprises two typical antipsychotic drugs selected from chlorpromazine and haloperidol. 5. The method according to any one of claims 1, 2, 3, and 4, wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril- . 6. A method of treating a patient suffering from treatment-resistant schizophrenia with cognitive impairments, comprising administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof: ##STR00004## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond, wherein the patient is a mammal and the patient fails to respond adequately to antipsychotic drugs which are at least one typical antipsychotic drug and at least one atypical antipsychotic drug selected from risperidone, olanzapine, quetiapine, and amisulpride. 7. The method of claim 6, wherein the at least one typical antipsychotic drug comprises two typical antipsychotic drugs selected from chlorpromazine, haloperidol and perphenazine. 8. The method of claim 6, wherein the at least one typical antipsychotic drug comprises one to two typical antipsychotic drugs selected from chlorpromazine and haloperidol. 9. The method of claim 6, wherein the at least one typical antipsychotic drug comprises two typical antipsychotic drugs selected from chlorpromazine and haloperidol. 10. The method according to any one of claims 6-9, wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril- .